Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Glycoprotein – e.g. – mucins – proteoglycans – etc.
Reexamination Certificate
2007-03-12
2008-12-30
Kam, Chih-Min (Department: 1656)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Glycoprotein, e.g., mucins, proteoglycans, etc.
C530S324000, C530S325000, C530S326000, C530S327000, C530S322000, C530S333000, C530S344000, C530S402000, C530S412000, C514S042000, C514S008100, C514S023000, C514S025000, C424S009100
Reexamination Certificate
active
07470776
ABSTRACT:
Compounds, compositions and methods for treating conditions characterized by leukocyte rolling are described. The compounds contain glycosulfopeptide structures comprising sulfated tyrosines and sialyated, fucosylated N-acetyllactosamino glycans. The glycosulfopeptides may be conjugated or complexed to other compounds for enhancing serum half-life or for controlled release, for example. Examples of conditions treated include inflammation, ischemia-reperfusion injury, rheumatoid arthritis, atherosclerosis, leukocyte-mediated lung injury, restenosis, and thrombosis.
REFERENCES:
patent: 4179337 (1979-12-01), Davis et al.
patent: 5047335 (1991-09-01), Paulson et al.
patent: 5180674 (1993-01-01), Roth
patent: 5382657 (1995-01-01), Karisiewicz et al.
patent: 5766897 (1998-06-01), Braxton
patent: 5821329 (1998-10-01), Lobl et al.
patent: 5827817 (1998-10-01), Larsen et al.
patent: 5858994 (1999-01-01), Kretzschmar et al.
patent: 5874261 (1999-02-01), Roth
patent: 5929036 (1999-07-01), McEver
patent: 5972885 (1999-10-01), Spira et al.
patent: 6136790 (2000-10-01), Toepfer et al.
patent: 6165509 (2000-12-01), Hoffman et al.
patent: 6177087 (2001-01-01), Greenwald et al.
patent: 6250469 (2001-06-01), Kline
patent: 6593459 (2003-07-01), Cummings et al.
patent: 7189828 (2007-03-01), Cummings et al.
patent: 2002/0026033 (2002-02-01), Cummings et al.
patent: 2003/0130174 (2003-07-01), Cummings et al.
patent: 2003/0144183 (2003-07-01), Cummings et al.
patent: 0577580 (1994-01-01), None
patent: 9411498 (1994-05-01), None
patent: 9706176 (1997-02-01), None
patent: PCT/US99/13455 (1999-06-01), None
patent: WO99/65712 (1999-12-01), None
patent: PCT/US02/33535 (2003-11-01), None
Amado et Ali., “A Family of Human 3-galactosyltransferases,” J. Biol. Chem., (May 22, 1998) 273 (21): 12770-12778.
Bierhuizen et al., “Expression Cloning of a cDNA encoding UDP-GlcNAc:Galβ1-3-GalNAc-R (GlcNAc to GalNAc) β1-6GlcNAc transferase by Gene Transfer Into CHO Cells Expressing Polyoma Large Tumor Antigen,”Proc. Natl. Acad. Sci. USA, 89:9326-9330, Oct. 1992.
Brockhausen et al., “Control of 0-glycan synthesis: specificty and inhibition of 0-glycan core 1 UDP-galactose: N-acetylgalactosamine- -R 3-galactosyltransferase from rat liver,” Biochem, Cell Biol., (1992) 70: 99-108.
Brockhausen et al., “Enzymatic basis for sialyl-Tn expression in human colon cancer cells,” Glycoconjugate Journal, (1998) 15:595-603.
Nishimune et al., “Detection of protein-protein interactionns in the nervous system using the two-hybrid system,” Trends Neurosci. (1996) 19, 261-266.
Pouyani et al., “PSGL-1 Recvognition of P-Selectin is Controlled by a Tyrosine Sulfation Consensus at the PSGL-1 Amino Terminus,”Cell. Oct. 20, 1995, vol. 83, No. 2, pp. 333-343, entire document.
Sako et al., “A sulfated Peptide Segment at the Amino Terminus of PSGL-1 is Critical for P-Selectin Binding,”Cell. Oct. 20, 1995, vol. 83, No. 2, pp. 323-331, entire document.
Seitz et al., “Chemoenzymatic Solution- and Solid-Phase Synthesos ofO-Glycopeptides of the Mucin Domain of MAdCAM-1, A General Route toO-LacNAc,O-Sialyl-LacNAc andO-Sialyl-Lewis-X Peptides,”J. Am. Chem. Soc., 119:8766-8776, 1997.
Sueyoshi et al., “Expression of Distinct Fucosylated Oligosaccharides and Carbohydrate-Mediated Adhesion Efficiency Directed by Two Different α-1,3-fucosyltransferases,”The Journal of Biological Chemistry, 269(51):32342-32350, 1994.
Thurnher et al., “T cell clones with normal or defective O-galactosylation from a patient with permanent mixed-field polyagglutinability,” Eur. J. Immunol., (1992) 22: 1835-1842.
Wilkins et al., Structures of the O-Glycans on P-Seletin Glycoprotein Ligand-1 from HL-60 Cells.Journal Biol. Chem. Aug. 2, 1996, vol. 271, No. 31, pp. 18732-18742, entire document.
Wilkins et al., “Tyrosine Sulfation of P-selectin Glycoprotein Ligand-1 Is Required for High Affinity Bnding to P-selectin,” J. BIol. Chem., (1995), vol. 270, No. 39, pp. 22677-22680.
Wünsch et al., “Synthesis of Cholecystokinin-Related Peptides and Their Biological Properties,”Biol Chem. Hoppe-Seylor. Apr. 1989, vol. 370, pp. 317-321, entire document.
Yamamoto et al., “Chemoenzymatic Synthesis of a Novel Glycopeptide Using a Microbial Endoglycosidase,”Caro. Res. Jan. 9, 1998, vol. 305, No. 3-4, pp. 415-422, entire document.
Cheng et al., “Mucin Biosynthesis,” J. Biol. Chem., (1982) 257 (11): 6251-6258.
Delhom et al., “Synthesis of Sulfated Bioactive Peptides Using Immobilized Arylsulfotransferase from Eubacterium,” sp.Biotechnol. Lett. May 1996, vol. 18, No. 5, pp. 609-614, entire document.
Granovsky et al., “UDPgalactose: glycoprotein-N-acetyl-D-galactosamine 3-3-D-galactosyltransferase activity synthesizing O-glycan core 1 is controlled by the amino acid sequence and glycosylation of glycopeptide substrates,” Euro. J. Biochem., (1994) 22:1039-1046.
Harris et al., “Pegylation A Novel Process for Modifying Pharmacokinetics,” Clin Pharmacokinet 2001; 40(7); 539-551.
Hicks, et al., “Glycosulfopeptides modeled on P-selectin glycoprotein ligand 1 inhibit P-selectin-dependent leukocyte rolling in vivo”, FASEB Journal, Sep. 2002, vol. 16, No. 11, pp. 1461-1462, especially p. 1462.
Hicks, et al., Glycosulfopeptides Modeled on PSGL-1 Inhibit P-selectin-dependent Leucocyte Rolling In Vivo. FASEB Journal, Mar. 2002, vol. 15, No. 5, p. A1052, see abstract.
Leppanen et al., “Binding of Glycosulopeptides to P-selectin Requires Stereospecific Contributions of Individual Tyrosine Sulfate and Sugar Residues” J. Biol. Chem., (2000) 275 (50): 39569-39578.
Leppanen et al., “A Novel Glycosulfopeptide Binds to P-selectin and Inhibits Leukocyte Adhesion to P-selectin” J. Biol. Chem., (1999) 274 (35): 24838-24848.
Lo-Guidice et al., “Sialylationa nd Sulfation of the Carbohydrate Chains in Respiratory Mucins from a Patient with Cystic Fibrosis,” J. Biol. Chem., (Jul. 1994) 269 (29): 18794-18813.
Lopez et al., “O-Glycosylation potential of lepidopteran insect cell lines,” Biochimica et Biophysica Acta (1999) 1427:49-61.
Meier et al., “The ELAM LIgand Fucosyltransferase, ELFT, Directs E-Selectin Binding to a Secreted Scaffold Protein: A Method to Produce and Purify Large Quantities of Specific Carbohydrate Structures,”Chemical Abstracts, XP-002124245, 119(17), 20/25/93.
Moore et al., “The P-Selectin Glycoprotein Ligand From Human Neutrophils Displays Sialylated, Fucosylated, O-Linked Poly-N-Acetyllactosamine,”The Journal of Biological Chemistry, 269(37):23318-23327, 1994.
Cummings Richard D.
McEver Rodger P.
Dunlap Codding P.C.
Kam Chih-Min
The Board of Regents of the University of Oklahoma
LandOfFree
Glycosulfopeptide inhibitors of leukocyte rolling and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Glycosulfopeptide inhibitors of leukocyte rolling and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Glycosulfopeptide inhibitors of leukocyte rolling and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4040860